Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2009-08-20FDA Approved: MITOXANTRONE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for MITOXANTRONE by Hospira, Inc., resulting in updated labeling for the product under the ANDA. The…
-
CLINICAL_TRIALS trial_result · 2009-08-17Clinical Trial Update: BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose [Phase 3]
Phase 3 trial update reporting Betaferon/Betaseron efficacy outcomes at a new dose for relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2009-08-13Clinical Trial Update: Natalizumab High Titer Immunogenicity and Safety [Phase 2]
Phase 2 study of natalizumab in multiple sclerosis reports on high-titer immunogenicity and related safety findings. Results were posted in …
-
CLINICAL_TRIALS withdrawal · 2009-07-22Clinical Trial Update: Phase II High-Dose Cyclophosphamide for Multiple Sclerosis [Phase 2]
A Phase II trial evaluating high-dose cyclophosphamide for multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2009-07-21Clinical Trial Update: Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b [Phase 2]
Phase 2 trial evaluating atorvastatin 40 mg in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b; study status…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2009-06-23Clinical Trial Update: EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis [NA]
Completed clinical trial studying early interferon beta-1a combined with atorvastatin for isolated clinical syndrome suggestive of multiple …
-
CLINICAL_TRIALS research · 2009-06-22Clinical Trial Update: Open-Label Natalizumab Safety Extension Study [Phase 3]
Open-label safety extension study of natalizumab in multiple sclerosis, a Phase 3 trial sponsored by Biogen; the study status is completed.
-
CLINICAL_TRIALS research · 2009-06-11Clinical Trial Update: Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS) [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating a new palliative care service for people severely affected by multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2009-06-10Clinical Trial Update: Immunogenicity and Safety Study of Serum-Free Avonex [Phase 2]
A Phase 2 trial assessing the immunogenicity and safety of Serum-Free Avonex in multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2009-06-08Clinical Trial Update: Open-Label Safety Extension Study of Avonex [Phase 4]
Open-label safety extension study of Avonex (interferon beta-1a) for multiple sclerosis has completed its Phase 4 safety extension.
-
CLINICAL_TRIALS trial_result · 2009-06-08Clinical Trial Update: Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe [Phase 3]
A Phase 3 clinical trial update evaluating patient satisfaction with a single-use autoinjector for delivering Avonex (interferon beta-1a) in…
-
CLINICAL_TRIALS trial_result · 2009-06-04Clinical Trial Update: A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers [Phase 1]
Phase 1 bioequivalence study evaluating serum-free Avonex versus Avonex-containing serum in healthy volunteers, sponsored by Biogen.
-
CLINICAL_TRIALS trial_result · 2009-06-04Clinical Trial Update: Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers [Phase 4]
A Phase 4 pharmacodynamic study update evaluating the therapeutic response and immunomodulatory effects of Avonex in multiple sclerosis pati…
-
EMA withdrawal · 2009-05-29EMA Application withdrawn: Biferonex (interferon beta-1a) — BioPartners GmbH
The EMA withdrew the application for Biferonex (interferon beta-1a) by BioPartners GmbH for multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2009-05-04Clinical Trial Update: Motor Imagery Practice in Neurological Rehabilitation [Phase 2]
A Phase 2 trial evaluating motor imagery practice in neurological rehabilitation has completed, with stroke, brain injury, and multiple scle…
-
FDA approval · 2009-04-03FDA Approved: BACLOFEN — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for Baclofen (BACLOFEN), updating the existing approval for the drug.
-
FDA approval · 2009-04-03FDA Approved: BACLOFEN — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for baclofen (generic), indicating an approval related to the product's labeling or formula…
-
FDA approval · 2009-03-26FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved Bayer HealthCare Pharmaceuticals Inc.'s supplemental application for Betaseron (interferon beta-1b). The approval relates to th…
-
CLINICAL_TRIALS research · 2009-03-12Clinical Trial Update: Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis
This document provides an update on a diagnostic study using quantitative imaging and spectroscopy in patients with multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2009-03-11Clinical Trial Update: Differential Immune Effects of Natalizumab
This completed trial update reports differential immune effects observed with Natalizumab in relapsing-remitting multiple sclerosis.
-
FDA approval · 2009-02-27FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved a supplemental application for Copaxone (glatiramer acetate) submitted by Teva Neuroscience, Inc., related to changes to th…
-
CLINICAL_TRIALS research · 2009-02-20Clinical Trial Update: Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis [Phase 1]
Phase 1 safety study of RTL1000 in individuals with multiple sclerosis is described, with the current trial status listed as unknown.
-
CLINICAL_TRIALS trial_result · 2009-02-19Clinical Trial Update: One Year Extension Study To Protocol C2/5/TZ:MS-05 [Phase 1, Phase 2]
One-year extension study to a Phase 1/2 trial (Protocol C2/5/TZ:MS-05) in spasticity associated with multiple sclerosis has been terminated.
-
CLINICAL_TRIALS trial_result · 2009-01-21Clinical Trial Update: Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated nighttime dosing of sublingual tizanidine (12 mg) for spasticity in patients with multiple sclerosis; t…
-
CLINICAL_TRIALS research · 2009-01-05Clinical Trial Update: Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS) [Phase 1]
Phase 1 clinical trial evaluating far infrared irradiation as a non-drug approach to managing and treating multiple sclerosis; the current s…